EP4335451A4 - Prophylaktisches oder therapeutisches mittel gegen akute niereninsuffizienz - Google Patents

Prophylaktisches oder therapeutisches mittel gegen akute niereninsuffizienz

Info

Publication number
EP4335451A4
EP4335451A4 EP22824797.9A EP22824797A EP4335451A4 EP 4335451 A4 EP4335451 A4 EP 4335451A4 EP 22824797 A EP22824797 A EP 22824797A EP 4335451 A4 EP4335451 A4 EP 4335451A4
Authority
EP
European Patent Office
Prior art keywords
prophylactic
therapeutic agent
renal failure
acute renal
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22824797.9A
Other languages
English (en)
French (fr)
Other versions
EP4335451A1 (de
Inventor
Etsuo Ohshima
Shinya Matsuno
Tsuneyo Nishino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of EP4335451A1 publication Critical patent/EP4335451A1/de
Publication of EP4335451A4 publication Critical patent/EP4335451A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP22824797.9A 2021-06-16 2022-05-31 Prophylaktisches oder therapeutisches mittel gegen akute niereninsuffizienz Pending EP4335451A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021100116 2021-06-16
PCT/JP2022/022228 WO2022264804A1 (ja) 2021-06-16 2022-05-31 急性腎不全の予防または治療剤

Publications (2)

Publication Number Publication Date
EP4335451A1 EP4335451A1 (de) 2024-03-13
EP4335451A4 true EP4335451A4 (de) 2025-05-14

Family

ID=84527435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22824797.9A Pending EP4335451A4 (de) 2021-06-16 2022-05-31 Prophylaktisches oder therapeutisches mittel gegen akute niereninsuffizienz

Country Status (5)

Country Link
US (1) US20240269223A1 (de)
EP (1) EP4335451A4 (de)
JP (1) JPWO2022264804A1 (de)
CN (1) CN117412763A (de)
WO (1) WO2022264804A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4461304A4 (de) * 2022-02-10 2026-01-07 Kyowa Hakko Bio Co Ltd Zusammensetzung zur prävention oder verbesserung von leberfunktionsstörungen
WO2024048479A1 (ja) * 2022-08-30 2024-03-07 国立大学法人東北大学 虚血再灌流傷害抑制

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4272759A1 (de) * 2021-02-08 2023-11-08 Kyowa Pharma Chemical Co., Ltd. Mittel zur prävention oder behandlung von entzündlichen erkrankungen und/oder schmerzerkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240601B1 (de) * 2007-12-27 2016-10-12 Compugen Ltd. Biomarker für die vorhersage von nierenläsion
CN102203619B (zh) * 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
ES2647461T3 (es) * 2009-12-18 2017-12-21 F. Hoffmann-La Roche Ag GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca
US11186610B2 (en) 2016-12-20 2021-11-30 Kyowa Hakko Bio Co., Ltd. Crystal of glutathione trisulfide dihydrate and method for producing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4272759A1 (de) * 2021-02-08 2023-11-08 Kyowa Pharma Chemical Co., Ltd. Mittel zur prävention oder behandlung von entzündlichen erkrankungen und/oder schmerzerkrankungen

Also Published As

Publication number Publication date
EP4335451A1 (de) 2024-03-13
WO2022264804A1 (ja) 2022-12-22
CN117412763A (zh) 2024-01-16
JPWO2022264804A1 (de) 2022-12-22
US20240269223A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
EP3556378A4 (de) Therapeutisches mittel für kardiomyopathie, alten myokardinfarkt und chronisches herzversagen
EP4335451A4 (de) Prophylaktisches oder therapeutisches mittel gegen akute niereninsuffizienz
IL308335A (en) Combination therapies
EP4342957A4 (de) Ölbeständiges mittel
EP4248997A4 (de) Therapeutikum oder prophylaktikum für covid-19
EP4243645A4 (de) Mehrschichtige flächenverkleidung
EP4398893A4 (de) Ibogain-kombinationsbehandlung
EP4378462A4 (de) Therapeutikum für covid-19
EP4114474C0 (de) Hämostatisches mittel
EP4214207A4 (de) 2-amino-3-carbonyl-imidazopyridin- und pyrazolopyridinverbindungen
EP3492091A4 (de) Prophylaktisches oder therapeutisches mittel für gefässerkrankungen
KR102358720B9 (ko) 전면형 호흡용 보호구
EP4373344A4 (de) Heilmittel
EP4066858A4 (de) Therapeutisches mittel für karzinomatöse peritonitis
EP4091633A4 (de) Prophylaktisches oder therapeutisches mittel bei demenz
EP4288212A4 (de) Heilmittel
EP4108876C0 (de) Drehbeschlag
EP4482466C0 (de) Kombinationstherapeutikum
JP1712642S (ja) チュニック
JP1722780S (ja) チュニック
JP1722837S (ja) チュニック
JP1722840S (ja) チュニック
EP4170433C0 (de) Entwicklungswalze
EP4316489A4 (de) Therapeutisches mittel gegen gangstörungen
EP4069243A4 (de) Kombinationstherapie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250410

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20250404BHEP

Ipc: G01N 33/68 20060101ALI20250404BHEP

Ipc: A61P 13/12 20060101ALI20250404BHEP

Ipc: A61K 31/198 20060101ALI20250404BHEP

Ipc: A61K 38/06 20060101AFI20250404BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251204